Publicacions en què col·labora amb Patricia Miranda Azpiazu (10)

2024

  1. Effect of antipsychotic drugs on group II metabotropic glutamate receptor expression and epigenetic control in postmortem brains of schizophrenia subjects

    Translational Psychiatry, Vol. 14, Núm. 1

  2. Ligand bias and inverse agonism on 5-HT2A receptor-mediated modulation of G protein activity in post-mortem human brain

    British Journal of Pharmacology

2021

  1. Correction to: Functional approaches to the study of G-protein-coupled receptors in postmortem brain tissue: [35S]GTPγS binding assays combined with immunoprecipitation (Pharmacological Reports, (2021), 73, 4, (1079-1095), 10.1007/s43440-021-00253-z)

    Pharmacological Reports

  2. Di-aryl guanidinium derivatives: Towards improved α2-Adrenergic affinity and antagonist activity

    European Journal of Medicinal Chemistry, Vol. 209

  3. Differential brain ADRA2A and ADRA2C gene expression and epigenetic regulation in schizophrenia. Effect of antipsychotic drug treatment

    Translational Psychiatry, Vol. 11, Núm. 1

  4. Functional approaches to the study of G-protein-coupled receptors in postmortem brain tissue: [35S]GTPγS binding assays combined with immunoprecipitation

    Pharmacological Reports, Vol. 73, Núm. 4, pp. 1079-1095

2019

  1. Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via Gαi1-proteins

    European Neuropsychopharmacology, Vol. 29, Núm. 12, pp. 1453-1463

2016

  1. Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia

    Science Signaling, Vol. 9, Núm. 410

  2. Substituted conformationally restricted guanidine derivatives: Probing the α2-adrenoceptors’ binding pocket

    European Journal of Medicinal Chemistry, Vol. 123, pp. 48-57

2014

  1. Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: Effect of antidepressant treatment

    Neuropharmacology, Vol. 86, pp. 311-318